IGHE and allergic asthma: In general, studies assessing omalizumab eligibility required a history of allergic asthma with sensitization to perennial allergens, demonstrated by specific serum IgE or positive skin prick testing, and patients also needed to fall within the omalizumab dosing range, determined by total IgE level and body weight.